MRTX News and Press, Mirati Therapeutics Inc. From 12/07/22

Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. The clinical-stage biotech specializes in antibody therapies to treat cancer. The stock has been falling all week. On Monday, the company released early phase 2 data on Adagrasib to treat non-small ce...

Mirati Therapeutics ( NASDAQ: MRTX ) is down 30% in Wednesday afternoon trading, a day after closing off 23% . The biotech Tuesday released phase 2 data on its candidate adagrasib in combination with Merck's ( MRK ) Keytruda (pembrolizumab) in non-small cell lung cancer. ...

Shares of Mirati Therapeutics (NASDAQ: MRTX) fell more than 20% in the early afternoon on Tuesday. The clinical-stage biotech company focuses on oncology therapies. It saw its shares plunge more than $19 from their closing price on Monday. The slump happened after the company anno...

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) PR Newswire Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promisi...

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study PR Newswire Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibi...

Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO PR Newswire SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology co...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com Mirati Therapeutics (NASDAQ: MRTX ) stock is a hot topic on Wednesday as the cancer drugmaker considers a potential takeover . According to insider sources, several large ...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group –  Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billi...

Mirati Therapeutics, Inc. (MRTX) Q3 2022 Earnings Conference Call November 08, 2022, 04:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Officer Charles Baum - President, Founder & Head of Research &am...

Mirati Therapeutics press release ( NASDAQ: MRTX ): Q3 GAAP EPS of -$3.09 beats by $0.40 . Revenue of $5.4M (-92.5% Y/Y) beats by $4.03M . MRTX's revenue of $71.8M in Q3 last year was due to the recognition of $66.6M of revenue associated with the transfer...